Vertex Buys Alpine Immune Sciences and its Kidney Disease Drug for US$4.9 B

By Lucy Haggerty

Pharma Deals Review: Vol 2024 Issue 4 (Table of Contents)

Published: 17 Apr-2024

DOI: 10.3833/pdr.v2024.i4.2870     ISSN: 1756-7874

Section: Mergers & Acquisitions



Vertex Pharmaceuticals has entered into an agreement to acquire clinical stage biotech, Alpine Immune Sciences, for US$65 per share or approximately US$4...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details